^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Biology (Basel)
    Title:

    Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma-A Real World Single-Center Analysis

    Published date:
    03/10/2022
    Excerpt:
    Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%)...Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed.
    DOI:
    10.3390/biology11030422
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma

    Published date:
    12/01/2018
    Excerpt:
    In patients treated with anti-PD-1, V600K (n=19) had superior outcomes than V600E (n=84), including response rate (53% vs 29%, p=0.059), PFS (median 19 vs 2.7 months, p=0.049) and overall survival (20.4 vs 11.7 months, p=0.081)….An independent cohort of V600E/K BRAF-mutant metastatic melanoma patients treated with anti-PD-1 immunotherapy (pembrolizumab or nivolumab)...
    DOI:
    10.1158/1078-0432.CCR-18-1680
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncologist
    Title:

    Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series

    Published date:
    06/20/2023
    Excerpt:
    A 19-year-old male presented with BRAF V600K-mutated stage IIID melanoma...He continued nivolumab monotherapy for an additional 6 months and has had an ongoing partial response on PET-CTs (with complete metabolic response) approximately 15 months after treatment.
    DOI:
    10.1093/oncolo/oyad184